Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized the treatment of advanced NSCLC, leading to the investigation of adjuvant EGFR-TKI treatment for early-stage disease. This evidence concerns the gene EGFR and non-small cell lung carcinoma.